EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent research progress in structural optimization and cancer treatment of novel selective FGFR inhibitors (2020–2025)

Rongfei Liu, Jinghui Qi, Yue Liu, Mingyue Hou, Mingyu Zhang, Xuan An, Jinxing Hu

International Immunopharmacology · 2026-03 · 172 · 116249

DOI: 10.1016/j.intimp.2026.116249 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2026-03. Verfasst von Rongfei Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shandong Second Medical University, Weifang, Shandong 261053, PR China. Hauptthemen laut MEDLINE: Receptors, Fibroblast Growth Factor, Neoplasms, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 122 Literaturangaben. Gefördert von: Shandong Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Abnormalities in protein tyrosine kinases (PTKs) are one of the primary drivers of cancer. As a receptor subfamily, fibroblast growth factor receptors (FGFRs) comprise four subtypes-FGFR1 to FGFR4. Their abnormal intracellular expression is a significant cause of tumorigenesis, making FGFRs key therapeutic targets in cancer treatment. This paper primarily summarizes the latest research advances in FGFR inhibitors, aiming to provide insights for future design and synthesis studies of FGFR inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Fibroblast Growth FactorNeoplasmsProtein Kinase InhibitorsAntineoplastic AgentsHumansAnimalsDrug DesignTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

Cancer therapyFGFRInhibitorSmall-molecule derivativesStructural optimization

Substanzen

Receptors, Fibroblast Growth FactorProtein Kinase InhibitorsAntineoplastic AgentsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • School of Pharmacy, Shandong Second Medical University, Weifang, Shandong 261053, PR China.
  • School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong 261053, PR China.
  • School of Pharmacy, Shandong Second Medical University, Weifang, Shandong 261053, PR China. Electronic address: jinxinghu2013@sdsmu.edu.cn.

Förderung

  • Shandong Province Natural Science Foundation

Zitieren

APA

Liu, R., Qi, J., Liu, Y., Hou, M., Zhang, M., An, X., & Hu, J. (2026). Recent research progress in structural optimization and cancer treatment of novel selective FGFR inhibitors (2020–2025). International Immunopharmacology, 172, 116249. https://doi.org/10.1016/j.intimp.2026.116249

Vancouver

Liu R, Qi J, Liu Y, Hou M, Zhang M, An X, et al. Recent research progress in structural optimization and cancer treatment of novel selective FGFR inhibitors (2020–2025). International Immunopharmacology. 2026;172:116249. doi:10.1016/j.intimp.2026.116249

BibTeX
@article{Liu2026,
  author = {Liu, Rongfei and Qi, Jinghui and Liu, Yue and Hou, Mingyue and Zhang, Mingyu and An, Xuan and Hu, Jinxing},
  title = {Recent research progress in structural optimization and cancer treatment of novel selective FGFR inhibitors (2020–2025)},
  journal = {International Immunopharmacology},
  year = {2026},
  volume = {172},
  pages = {116249},
  doi = {10.1016/j.intimp.2026.116249}
}
Kostenlos starten →